Crossmark

Treatment of thrombotic microangiopathy associated with systemic lupus erythematosus with low-dose rituximab as an induction agent and belimumab as a maintenance agent

Crossref DOI link: https://doi.org/10.1186/s12887-025-05506-x

Published Online: 2025-02-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Zhenle

Liu, Suwen

Zong, Zihan

Li, Qian

Yu, Lichun

Sun, Shuzhen
License Information

Text and Data Mining valid from 2025-02-26

Version of Record valid from 2025-02-26
More Information

Article History

Received: 8 October 2024

Accepted: 11 February 2025

First Online: 26 February 2025

Declarations

:

: This is not applicable, as this study is a case report.

: Written informed consent for publication was obtained from the patients’ caregivers.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below